ENDPOINTS NEWS35m
Sage turns down Bio­gen's buy­out of­fer and will look at oth­er op­tions
Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...
The Pharma Letter36m
Eisai and Biogen gain FDA approval for monthly Leqembi
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...